Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens (2Gether)

26 novembre 2018 aggiornato da: Centers for Disease Control and Prevention

This trial will evaluate a multi-component, clinic-based intervention aimed at increasing dual protection strategy selection and adherence among young African American females at an urban family planning clinic. Dual protection is the use of contraceptive strategies to prevent both unintended pregnancy (UIP) and sexually transmitted infections (STIs). This is an unblinded randomized controlled trial; participants will either get the interactive multimedia platform focused on DP strategies with intervention arm counseling or the standard of care arm counseling.

The study will recruit 710 African American females aged 14-19 who are attending the Grady Health System (GHS) Teen Services Clinic (TSC) in Atlanta, Georgia, for reproductive health care.

The trial will recruit and enroll 710 young women presenting to the clinic for clinical care who have the following characteristics:

  • self-identify as African American,
  • 14-19 years of age,
  • have had vaginal sex with a male partner in the past 6 months,
  • HIV-negative by self-report,
  • not pregnant,verified by urine pregnancy test,
  • no desire to be pregnant in next 12 months,
  • plan to stay in the Atlanta area for the next year,
  • are willing to provide contact information, and
  • were not previously enrolled in the pilot study of this intervention.

Those enrolled will be in the study for 12 months. Young women who are eligible and give written consent or assent for study participation will be enrolled. Half will be randomized to the control arm, half to the intervention arm.

  1. Control arm (standard of care) includes individual clinical care and standard of care counseling consistent with protocols at the TSC, with study visits for data collection at enrollment, 6 months, and 12 months, during which any medical care or counseling that they would normally get will also be provided. Control arm participants will also get telephone calls from clinic staff to update their contact information and remind them of upcoming visits at 3 weeks and 5 months after the enrollment visit, and at 3 weeks and 5 months after the 6 month visit.
  2. Intervention arm, consisting of the following intervention components:

    1. Enrollment visit

      • A culturally-appropriate interactive multimedia platform focused on DP strategies and designed to prepare the individual for selection of a DP strategy.
      • Individual intervention arm counseling to select the DP strategy that is best suited for the participant (by a clinic health care provider).
      • Individual intervention arm counseling to build skills for correct and consistent use of the selected DP strategy (by a nurse educator (NE)).
    2. Booster counseling via phone at about 3 weeks and 5 months after the enrollment visit, and at about 3 weeks and 5 months after the 6 month visit (by an NE).
    3. 6 month visit

      • An abbreviated version of the interactive multimedia platform focused on dual protection strategies and strategy adherence.
      • Individual intervention arm counseling to reinforce skills for correct and consistent use of the DP strategy (by an NE).

At the final study visit at 12 months there is no difference between the counseling provided to the two groups; participants in both arms will receive the clinic standard of care.

Participants in both arms of the study will follow the same data collection procedures throughout the study:

  • At all three study visits, participants in both arms will receive urine pregnancy and STI tests and complete an audio computer assisted self-interview (ACASI) questionnaire.
  • At 3 and 9 months after enrollment, participants in both arms will receive a data collection call with administration of a telephone questionnaire.

Throughout the study, all participants will be encouraged to come in for evaluation if they have any concerns. Any data from pregnancy or STI testing at these interim clinic visits will be later collected via chart review. If participants seek reproductive health care at other facilities during the study period, records will be requested with participant permission, and data from pregnancy or STI testing at these outside clinic visits will be collected via review of records received.

We will examine the efficacy of the intervention arm relative to control arm across the following primary behavioral and biologic outcomes over the 12 months of follow-up:

  1. Self-reported dual protection strategy selection
  2. Self-reported dual protection strategy adherence
  3. Incidence of pregnancy or infection with chlamydia, gonorrhea or trichomonas (as confirmed by laboratory testing)

A small pilot study was be conducted prior to the initiation of enrollment in the main study.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

709

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30303
        • Grady Health System Teen Services Clinic

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 14 anni a 19 anni (Bambino, Adulto)

Accetta volontari sani

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • female,
  • self-identify as African American,
  • 14-19 years of age,
  • present to clinic on date of potential enrollment for clinical care,
  • has had vaginal sex with a male partner at least once in the past 6 months,
  • HIV-negative by self-report,
  • not currently pregnant (verified by urine pregnancy test),
  • desire to avoid pregnancy for at least 12 months,
  • plan to be in the Atlanta area for the next 12 months,
  • competent to participate in consenting or assenting process per recruiter evaluation,
  • willing to provide contact information, and
  • not previously enrolled in the pilot study of this intervention.

Exclusion Criteria:

  • pregnant
  • HIV positive

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Altro: Control
The control arm receives the clinic standard of care counseling. This includes individual clinical care and counseling consistent with protocols at the Grady Health System Teen Services Clinic, with study visits at enrollment, 6 months, and 12 months, during which any medical care or counseling included in the clinic standard of care will be provided. All control group members will see a provider on the day of enrollment. Control arm participants will get phone calls from clinic staff to update their contact information and remind them of upcoming appointments at 3 weeks and 5 months after both the enrollment visit and the 6 month visit. Participants may visit the clinic at any time and will be encouraged to come into the clinic for any concerns. If they have an interim visit during the study period, they will receive the clinic standard of care.
Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
Sperimentale: Intervention
  1. Enrollment

    • Interactive multimedia platform focused on DP strategies.
    • Intervention arm counseling by a health care provider to select DP strategy.
    • Intervention arm counseling and skill-building by a nurse educator (NE) on correct, consistent use of DP strategy.
  2. Booster counseling by an NE via phone at 3 weeks and 5 months after both the enrollment visit and the 6 month visit.
  3. 6 month visit

    • Abbreviated version of the interactive multimedia platform on DP strategies and adherence.
    • Intervention arm counseling by an NE to reinforce skills for correct, consistent use of DP strategy.
  4. Interim visits: Participants may visit the clinic at any time. If intervention group members visit the clinic for STI treatment or to switch birth control method, providers and/or NEs will follow structured counseling guides. If they have an interim visit for another reason, they will receive the clinic standard of care.
An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
Altri nomi:
  • MMDP
Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Participant selection of an effective dual protection (DP) strategy
Lasso di tempo: 6 months

Whether or not a participant self-reports having selected an effective DP strategy. An effective DP strategy is defined as one of the following:

  • Abstinence from vaginal sex;
  • Effective non-barrier contraceptive method [including intrauterine device (IUD), Implant, Depo, or contraceptive pill, patch or ring] with consistent condom use;
  • Consistent condom use only
6 months
Participant report of adherence to DP strategy
Lasso di tempo: 3 months

By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes:

  • Whether or not DP strategy was used at last sex
  • Whether or not DP strategy was used consistently during last 3 month time period
  • Estimated proportion of time adherent to DP strategy over last 3 months
3 months
Time to first biologic event (pregnancy or diagnosis with STI) in participants
Lasso di tempo: Within 12 month period following enrollment
Measured by date of positive lab test ("biologic event" refers to a positive pregnancy test or diagnosis with chlamydia, gonorrhea or trichomonas infection).
Within 12 month period following enrollment
Incidence of pregnancy and sexually transmitted infections (STIs)
Lasso di tempo: Within 12 month period following enrollment
Includes the proportion of participants with a lab-confirmed diagnosis of pregnancy or lab-confirmed diagnosis with infection with chlamydia, gonorrhea or trichomonas within the 12 month follow-up period (testing either performed at study site clinic and documented at study visits and via chart review, or diagnosed by outside labs with documentation obtained via release of information procedures)
Within 12 month period following enrollment
Participant selection of an effective dual protection (DP) strategy
Lasso di tempo: 12 months

Whether or not a participant self-reports having selected an effective DP strategy. An effective DP strategy is defined as one of the following:

  • Abstinence from vaginal sex;
  • Effective non-barrier contraceptive method [including intrauterine device (IUD), Implant, Depo, or contraceptive pill, patch or ring] with consistent condom use;
  • Consistent condom use only
12 months
Participant report of adherence to DP strategy
Lasso di tempo: 6 months

By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes:

  • Whether or not DP strategy was used at last sex
  • Whether or not DP strategy was used consistently during last 3 month time period
  • Estimated proportion of time adherent to DP strategy over last 3 months
6 months
Participant report of adherence to DP strategy
Lasso di tempo: 9 months

By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes:

  • Whether or not DP strategy was used at last sex
  • Whether or not DP strategy was used consistently during last 3 month time period
  • Estimated proportion of time adherent to DP strategy over last 3 months
9 months
Participant report of adherence to DP strategy
Lasso di tempo: 12 months

By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes:

  • Whether or not DP strategy was used at last sex
  • Whether or not DP strategy was used consistently during last 3 month time period
  • Estimated proportion of time adherent to DP strategy over last 3 months
12 months
Participant selection of an effective dual protection (DP) strategy
Lasso di tempo: At enrollment visit

Whether or not a participant self-reports having selected an effective DP strategy. An effective DP strategy is defined as one of the following:

  • Abstinence from vaginal sex;
  • Effective non-barrier contraceptive method [including intrauterine device (IUD), Implant, Depo, or contraceptive pill, patch or ring] with consistent condom use;
  • Consistent condom use only
At enrollment visit

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Participant level of reproductive health knowledge (percentage correct of knowledge questions)
Lasso di tempo: 6 months
Knowledge about contraceptives and STIs, as measured by correct answers to knowledge questions on ACASI questionnaires.
6 months
Participant intention to use DP strategy
Lasso di tempo: 6 months
Whether or not participant self-reports intention to use an effective DP strategy in the future, as measured by responses on ACASI questionnaires.
6 months
Participant reproductive health self-efficacy
Lasso di tempo: 6 months
Whether or not participant reported high self-efficacy for condom use, contraceptive use, and communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires.
6 months
Participant report of STI testing
Lasso di tempo: 6 months
Frequency of self-reported STI testing by participant and partner(s) and result-sharing with partner(s), as measured by responses to ACASI questionnaires.
6 months
Participant report of partner communication
Lasso di tempo: 6 months
Self-reported frequency of communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires.
6 months
Participant level of reproductive health knowledge (percentage correct of knowledge questions)
Lasso di tempo: 12 months
Knowledge about contraceptives and STIs, as measured by correct answers to knowledge questions on ACASI questionnaires.
12 months
Participant intention to use DP strategy
Lasso di tempo: 12 months
Whether or not participant self-reports intention to use an effective DP strategy in the future, as measured by responses on ACASI questionnaires.
12 months
Participant report of STI testing
Lasso di tempo: 12 months
Frequency of self-reported STI testing by participant and partner(s) and result-sharing with partner(s), as measured by responses to ACASI questionnaires.
12 months
Participant reproductive health self-efficacy
Lasso di tempo: 12 months
Whether or not participant reported high self-efficacy for condom use, contraceptive use, and communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires.
12 months
Participant report of partner communication
Lasso di tempo: 12 months
Self-reported frequency of communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires.
12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Melissa Kottke, MD MPH MBA, Emory University; Grady Health System
  • Investigatore principale: Jessica Sales, PhD, Emory University
  • Investigatore principale: Athena Kourtis, MD PhD MPH, Centers for Disease Control and Prevention
  • Direttore dello studio: Peggy Goedken, MPH, Emory University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 marzo 2015

Completamento primario (Effettivo)

1 agosto 2018

Completamento dello studio (Effettivo)

1 agosto 2018

Date di iscrizione allo studio

Primo inviato

24 luglio 2014

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2014

Primo Inserito (Stima)

14 novembre 2014

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

27 novembre 2018

Ultimo aggiornamento inviato che soddisfa i criteri QC

26 novembre 2018

Ultimo verificato

1 novembre 2018

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CDC-NCCDPHP-6588
  • DP12-001 (Altro numero di sovvenzione/finanziamento: CDC)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Standard of care counseling

Sottoscrivi